A total of 48 patients with EBC (median age 50.5 years) [34 hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−), 5 HER2+, 9 triple-negative breast cancer) were included. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.